OBJECTIVE: To characterize sperm parameters from thawed semen samples of men with different cancers who cryopreserved semen before oncologic therapy. DESIGN: Retrospective cohort study. SETTING: Tertiary academic medical center. PATIENT(S): 1,010 semen samples collected between 1994 to 2010. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Mean total motile count (TMC), change in percentage motility and percentage survival (100 * [postthaw % motility/raw % motility]) for each cancer compared with data from samples of men without cancer (the "procreative management" group), and proportion of postthaw samples with TMC >5 × 10(6). RESULT(S): The procreative management group had the best raw and postthaw semen quality. The best raw and postthaw semen quality for cancer patients occurred in those with prostate cancer (TMC of 155.1 and 53.2 × 10(6), respectively) and the worst in those with leukemias. Lymphoid leukemias demonstrated the worst raw TMC (26.8 × 10(6)), but myeloid leukemias displayed the worst postthaw TMC (6.9 × 10(6)). The testicular cancer group was the only group with a statistically significantly lower chance of having TMC >5 × 10(6). CONCLUSION(S): Men with testicular cancer were most commonly referred for sperm cryopreservation and were the only group that was statistically significantly less likely to have TMC >5 × 10(6) on postthaw semen analysis. The most severe reduction in TMC was seen in the myeloid leukemia group, suggesting that these patients along with men with testis cancer and those with lymphoid leukemia should be counseled to provide increased numbers of specimens for fertility preservation. Published by Elsevier Inc.
OBJECTIVE: To characterize sperm parameters from thawed semen samples of men with different cancers who cryopreserved semen before oncologic therapy. DESIGN: Retrospective cohort study. SETTING: Tertiary academic medical center. PATIENT(S): 1,010 semen samples collected between 1994 to 2010. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Mean total motile count (TMC), change in percentage motility and percentage survival (100 * [postthaw % motility/raw % motility]) for each cancer compared with data from samples of men without cancer (the "procreative management" group), and proportion of postthaw samples with TMC >5 × 10(6). RESULT(S): The procreative management group had the best raw and postthaw semen quality. The best raw and postthaw semen quality for cancerpatients occurred in those with prostate cancer (TMC of 155.1 and 53.2 × 10(6), respectively) and the worst in those with leukemias. Lymphoid leukemias demonstrated the worst raw TMC (26.8 × 10(6)), but myeloid leukemias displayed the worst postthaw TMC (6.9 × 10(6)). The testicular cancer group was the only group with a statistically significantly lower chance of having TMC >5 × 10(6). CONCLUSION(S): Men with testicular cancer were most commonly referred for sperm cryopreservation and were the only group that was statistically significantly less likely to have TMC >5 × 10(6) on postthaw semen analysis. The most severe reduction in TMC was seen in the myeloid leukemia group, suggesting that these patients along with men with testis cancer and those with lymphoid leukemia should be counseled to provide increased numbers of specimens for fertility preservation. Published by Elsevier Inc.
Authors: James M Hotaling; Darshan P Patel; Christopher Vendryes; Natalya A Lopushnyan; Angela P Presson; Chong Zhang; Charles H Muller; Thomas J Walsh Journal: Asian J Androl Date: 2016 Jan-Feb Impact factor: 3.285
Authors: Xiao Liu; Bo Liu; Shasha Liu; Yang Xian; Wenrui Zhao; Min Jiang; Bin Zhou; Fuping Li Journal: Transl Cancer Res Date: 2021-12 Impact factor: 1.241